ORACLE®



CERN openlab "IT in Healthcare" Workshop

Miguel Coelho
Solution Architect
EMEA Healthcare and Life Sciences Industry Solutions Group
November 11, 2014









Safe Harbor Statement

The following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle's products remains at the sole discretion of Oracle.

Program Agenda

- 1 Setting the scene
- What is the opportunity?
- How can Oracle help?
- Oracle experience
- 5 Discussion

Oracle Addresses the Full Healthcare and Life Sciences Ecosystem

Life Sciences/ Healthcare Healthcare Government Pharma **Providers** & Regulators Insurances/ Payers

Market and Trends

Shifting Payment Models



Changing Science



Increasing Data Volumes



Regulatory Pressures



Point Applications

Limited, not scalable, and reinforce silos

Homegrown Tools


Expensive to build and maintain

Established Solutions

Often proprietary, closed, and inflexible




Convergence Between Healthcare and Life Sciences Leading to Personalized Healthcare





In the Coming Decade Healthcare Data Will Be Big, Real Big





A Big Data Example


With existing data



National Cancer Institute, Oracle & SAIC

Identifying Relationships between Gene to Cancer Interaction

- Analyzed 20 million medical publication abstracts in order to cross-reference the relationships between 17000 genes and five major cancer types
- Cross-referenced genes from 60 Million patients and miRNA for a simulated 900 Million population
- Results: understanding additional layers of the pathways these genes operate in and the drugs that target them is expected to help researchers accelerate their work in areas of importance for all humanity





"Our mouths were open in amazement"

- Dr. Robert Stephens
- Director of Bioinformatics,
 National Cancer Institute


http://ctovision.com/2012/11/the-winner-of-the-2012-government-big-data-solutions-award-is-the-national-cancer-institute/





Industry Trends

Significant reduction in cost of genome sequencing



Increase in real-world data



Aggregation and analysis of Big Data



More than half of clinical trials already have a molecular biomarker component



Patient stratification to identify population subsets most likely to respond to a therapy



Cloud technologies are enhancing R&D collaboration






Vision research ar healthcare

Facilitate researchers access to clinical and genomics patient de clinical and genomics patient data across the world to advance medical research and its translation to better

Translational Research

On the path to Personalized Medicine



Ability to discover high quality biomarkers which in turn will enable early detection, rapid effective treatment and improved quality of care for patients with considerable associated cost savings ("right treatment for the right patient")



Disease-specific SNPS

Non-disease SNPS



A Healthcare Research Database

The opportunity for Medical Researchers

Research Entity

- Attract quality scientists by enabling them with access to data
- Attract more clinical trials by using data for Trial certainty
- Break down organizational barriers between Clinical, Research, Biostatisticians, IT, Business and across institutions to enable knowledge sharing
- Enable convergence of Science,
 Medicine, Biotech and ICT to
 produce next generation products
 and personalized genomic medicine


Industry

- Identify markers that will predict needs and risks of patients so interventions can be pre-emptive.
- Improve hypotheses and decision making – fail early
- Quickly and easily identify cohorts with similar characteristics
- Move from trial's looking for patients to trials designed specifically for patients, fast tracking clinical trial process from years to months
- Benefit from global collaboration around hard to find diseases and mutations

Technology


- Collapse research cycle times and minimize demands on IT by providing self-service analytics to researchers and clinicians
- Integrate the data once and re-use for many purposes
- Increase productivity and break barriers to entry by providing an open platform – Oracle tools, customer tools, researcher tools
- Flexible Oracle platform only buy and use the Oracle components you need
- Better TCO by leveraging prebuilt healthcare components





Oracle Connected Health


Increasing outcomes through an interoperable healthcare ecosystem and allowing for the subsequent analysis of health data across facilities and organizations



Healthcare Interoperability
 Provide a unified patient medical summary to improve outcomes, increase healthcare efficiency and reduce costs



Healthcare Analytics
 Use healthcare data for disease management and surveillance, comparative effectiveness research, population health analysis, etc.



Medical Research
 Combine healthcare + omics data to empower researchers in translating science into clinical treatments faster, and with greater certainty

Security

Platform for Healthcare Analytics & Medical Research

Analytics Applications

Analytics Tools

(Visualization, Query Engines, Statistical Languages ...)

Healthcare Data

(Administrative, Clinical, Financial...)


Omics Data

(Genomics, Reference Data Sets...)

Data Integration, MDM & Other Services



Platform for Healthcare Analytics & Medical Research





Platform for Healthcar

The power of Clinical and Genomics data in one single platform


• Find patients that are poor responders for drug Y and have a mutation in the promoter region of Gene X

What is the expression level of TP53 mutants by cancer tissue

• How many patients have disease Z, responded to treatment, have a chromosome 18 deletion and have blood samples in the biobank?

• Do mutations in the coding sequence of Gene X perturbs its expression across all of my projects?





De-Identification Re-Identification

Terminology Services Patient Linkage

Unit of Measures NLP Data Integration, MDM & Other Services


Secure Files Job Scheduling **Data Quality**

Data Quality Governance End to End **Data Lineage**


In-memory analysis **HW/SW Integration**



Platform for Healthcare Analytics & Medical Research



Platform for Healthcare Analytics & Medical Research



Oracle Enterprise Healthcare Analytics (EHA)

Healthcare Data Warehouse Foundation (HDWF)



Integrated View of Clinical, Financial, Operational, & Research Data Across the Provider Enterprise

- Logical & 3NF Optimized Physical Model
 - Logical Data Model: 1000+ entities and 5,500+ attributes
 - Physical Data Model: 538 tables and 12,000 columns (5742 non-key columns)
- Engineered specifically for Providers to lower DW/Analytics development cost, time, & risk
 - Well organized model makes it easy for analytic application developers
 - HDWF design also facilitates data capture, cleansing, and integration
 - HDWF enables rapid deployment of pre-built apps from Oracle & our partner ecosystem
 - Data model is extensible, scalable, secure
 - Supports enterprise-grade software & hardware tools from the world's leading enterprise software vendor



25

Oracle Translational Research Center Cohort Explorer





Real-Time Big Data Queries No Longer a Dream

Oracle Omics Data Bank Performance

% of Use Cases	Response Time
56	< 1 Second
38	1 – 10 Seconds
6	10 – 30 Seconds
0	30 – 60 Seconds
	60+ Seconds

100k Genomes, 100 Concurrent Users



Next Level: the Oracle Health Sciences Network

Secure, Global, Cloud-Based Collaboration R&D



Ensuring:

- Protocol design and validation
- Patient recruitment
- Provides participants full control over their data
- Protects institutional IP
- Respects patient consent
- Enables real-time collaboration



MD Anderson



Background / Needs

- Moon Shots initiative to cure 6
 cancers in 5 years
- One source of truth for all data
 - Improve data availability to the enterprise
 - Scalable to address 30-40% data growth per year
- Rapid time to value





Fast implementation

– in use within 6 months



Streamlined pharmacy operations and achieved significant ROI



Supporting more than 1 million patients spanning a 70-year period



ASE STUDY

UPMC



Background / Needs

- Aggregate data from 200+ sources
- Integrate healthcare and payer data
- Provide better clinical insights for:
 - Treatment effectiveness
 - Cost variations
 - Disease prevention
- Simplify data delivery for analysis

Results With Oracle



Integration of clinical and genomic information



Preliminary identification of genes and pathways unique to pre- and post-menopausal breast cancer patients




Consolidation of multiple data marts









THE FUTURE OF OUR INDUSTRY IS BRIGHT

Hardware and Software Engineered to Work Together

ORACLE®